Analysis of a case of thrombocytopenia induced by pralsetinib

Published on Sep. 01, 2023Total Views: 1602 times Total Downloads: 591 times Download Mobile

Author: Hao-Chun TANG ¹ Zheng-Zheng XIA ¹ Han YU ²  Jun MENG ¹

Affiliation: 1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China 2. School of Pharmacy, Chongqing Medical University, Chongqing 400016, China

Keywords: Pralsetinib Thrombocytopenia Adverse drug reaction

DOI: 10.19960/j.issn.1005-0698.202308016

Reference: Hao-Chun TANG, Zheng-Zheng XIA, Han YU, Jun MENG.Analysis of a case of thrombocytopenia induced by pralsetinib[J].Yaowu Liuxingbingxue Zazhi,2023, 32(8):956-960.DOI: 10.19960/j.issn.1005-0698.202308016. [Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

In this paper, a case of a 58-year-old RET fusion of positive patient with advanced non-small cell lung cancer, who appeared grade 4 thrombocytopenia after receiving pralsetinib 400 mg qd regularly for anti-tumor therapy, was reported. Before the treatment, the patient's hemogram was normal. After continuous administration of pralsetinib for 27 days, the patient's platelet count (Plt) began to decrease dramatically, reaching the lowest level of 14×10⁹·L^-1. Even symptomatic treatment aimed at increasing platelet did not result in significant improvement. After conducting an adverse reaction causality assessment for thrombocytopenia, it was considered to be an adverse reaction induced by pralsetinib. Therefore, pralsetinib treatment was temporarily suspended and symptomatic treatment was given. Subsequently, the patient's condition gradually improved, and the Plt recovering to 94×10⁹·L^-1 10 days later . After the patient's hemogram gradually stabilized, the dosage of pralsetinib was adjusted to restart anti-tumor therapy. Clinical pharmacists determined that platinib-induced thrombocytopenia was likely to be caused by platinib through the association evaluation of adverse reactions, monitored the patient for symptomatic treatment, and proposed dosage adjustment suggestions for restarting platinib after the patient's Plt returned to normal. This case suggests that the clinical use of pratinib should be vigilant against thrombocytopenia adverse reactions, do a good job of pharmaceutical care, and timely drug analysis and symptomatic treatment after adverse reactions.

Full-text

Please download the PDF version to read the full text: download

References

1.高青云, 苏俊威, 肖法嫚,等. RET融合阳性晚期非小细胞肺癌治疗进展[J]. 中国肺癌杂志, 2021, 24(12): 853-861. [Gao QY, Su JW, Xiao FM, et al. Advances in the treatment of RET fusion-positive advanced non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2021, 24(12): 853-861.] DOI: 10.3779/j.issn.1009-3419. 2021.101.43.

2.Markham A. Pralsetinib[J]. First Approval Drugs, 2020, 80(17): 1865-1870. DOI: 10.1007/s40265-020-01427-4.

3.Wright KM. FDA approves pralsetinib for treatment of adults with metastatic RET fusion-positive NSCLC[J]. Oncology (Williston Park), 2020, 34(10): 406-406, 431. DOI: 10.46883/ONC.2020.3410.0406.

4.Griesinger F, Curigliano G, Thomas M, et al. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial[J]. Ann Oncol, 2022, 33(11): 1168-1178. DOI: 10.1016/j.annonc.2022.08.002.

5.Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study[J]. Lancet Oncol, 2021, 22(7): 959-969. DOI: 10.1016/S147 0-2045(21)00247-3.

6.Blog: Tyrosine kinase inhibitors can have an effect on platelet function[EB/OL]. https://plateletservices.com/2020/04/blog-tyrosine-kinase-inhibitors-can-have-an-effect-on-platelet-function/.

7.Grey W, Chauhan R, Piganeau M, et al. Activation of the receptor tyrosine kinase RET improves long-term hematopoietic stem cell outgrowth and potency- ScienceDirect[J]. Blood, 2020, 136(22): 2535-2547. DOI: 10.1182/blood.2020006302.

8.王理伟. 《肿瘤治疗相关血小板减少症的临床管理专家共识》述评[J]. 肿瘤, 2021, 41(12): 828-831. [Wang LW. Comments on concensus on clinical management of cancer therapyrelated thrombocytopenia[J]. Tumor, 2021, 41(12): 828-831.] DOI: 10.3781/j.issn.1000-7431. 2021.2112-0945.

9.中华医学会肿瘤学分会肿瘤支持康复治疗学组. 肿瘤治疗相关血小板减少症的临床管理专家共识[J]. 肿瘤, 2021, 41(12): 812-827. DOI: 10.3781/j.issn.1000-7431. 2021.2111-0882.

10.Network NCC. NCCN Clinical practice guidelines in oncology hematopoietic Growth Factors version 4.2021[EB/OL]. (2021-05-20) [2021-08-08]. https:// www.nccn.org/guidelines/guidelines-detail?category=3&id=1493.

11.FDA. GAVRETO (pralsetinib)[EB/OL]. (2022-09-28) [2023-05-11]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf.

12.Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers [J]. Cancer Discov, 2018, 8(7): 836-849. DOI: 10.1158/2159-8290.CD-18-0338.